|
CDKN2B-AS1
|
0.160 |
GeneticVariation
|
disease |
BEFREE |
Six inheritance models showed that ANRIL rs2151280 variant genotype (A>G) was related to the susceptibility of glioma, while the other three lncRNAs showed no association.
|
31489712 |
2019 |
|
CDKN2B-AS1
|
0.160 |
GeneticVariation
|
disease |
GWASCAT |
Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21.
|
29743610 |
2018 |
|
CDKN2B-AS1
|
0.160 |
GeneticVariation
|
disease |
BEFREE |
We hypothesized that CCDKN2A/B rs1063192 and rs4977756 and also the long noncoding RNA (lncRNA) CDKN2BAS rs2157719 glioma susceptibility polymorphisms identified by genome-wide association studies may contribute to medulloblastoma predisposition.
|
29314442 |
2018 |
|
CDKN2B-AS1
|
0.160 |
Biomarker
|
disease |
BEFREE |
We consider that lncRNA ANRIL is a potential therapeutic and diagnostic target for glioma, and miR-203a plays an important role in the biological function of lncRNA ANRIL in glioma.
|
30197521 |
2018 |
|
CDKN2B-AS1
|
0.160 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors.
|
28346443 |
2017 |
|
CDKN2B-AS1
|
0.160 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, we found an association between rs1412829 and rs4977756 (9p21.3, CDKN2B-AS1) and global DNA methylation pattern in glioma, for which a trend was seen also in the TCGA glioblastoma dataset.
|
27780202 |
2016 |
|
CDKN2B-AS1
|
0.160 |
GeneticVariation
|
disease |
BEFREE |
We confirmed the association with glioma risk for variants within five genomic regions: 8q24.21 (CCDC26), 9p21.3 (CDKN2B-AS1), 11q23.3 (PHLDB1), 17p13.1 (TP53), and 20q13.33 (RTEL1).
|
25713050 |
2015 |
|
CDKN2B-AS1
|
0.160 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study identifies multiple susceptibility loci for glioma.
|
26424050 |
2015 |
|
CDKN2B-AS1
|
0.160 |
GeneticVariation
|
disease |
BEFREE |
We conducted a new independent GWAS of glioma using 1,856 cases and 4,955 controls (from 14 cohort studies, 3 case-control studies, and 1 population-based case-only study) and found evidence of strong replication for three of the seven previously reported associations at 20q13.33 (RTEL), 5p15.33 (TERT), and 9p21.3 (CDKN2BAS), and consistent association signals for the remaining four at 7p11.2 (EGFR both loci), 8q24.21 (CCDC26) and 11q23.3 (PHLDB1).
|
22886559 |
2012 |
|
CDKN2B-AS1
|
0.160 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association study of glioma and meta-analysis.
|
22886559 |
2012 |
|
CDKN2B-AS1
|
0.160 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study of glioma and meta-analysis.
|
22886559 |
2012 |
|
CDKN2B-AS1
|
0.160 |
GeneticVariation
|
disease |
GWASCAT |
Chromosome 7p11.2 (EGFR) variation influences glioma risk.
|
21531791 |
2011 |
|
CDKN2B-AS1
|
0.160 |
GeneticVariation
|
disease |
GWASDB |
Chromosome 7p11.2 (EGFR) variation influences glioma risk.
|
21531791 |
2011 |
|
CDKN2B-AS1
|
0.160 |
GeneticVariation
|
disease |
GWASDB |
Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility.
|
19578366 |
2009 |
|
CDKN2B-AS1
|
0.160 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association study identifies five susceptibility loci for glioma.
|
19578367 |
2009 |
|
CDKN2B-AS1
|
0.160 |
GeneticVariation
|
disease |
GWASCAT |
Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility.
|
19578366 |
2009 |
|
CDKN2B-AS1
|
0.160 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study identifies five susceptibility loci for glioma.
|
19578367 |
2009 |